Simvastatin increases the in vivo activity of the first-line tuberculosis regimen | Zendy

Ciaran Skerry | Zendy; Michael L. Pinn | Zendy; Natalie Bruiners | Zendy; Richard Pine | Zendy; Maria Laura Gennaro | Zendy; Petros C. Karakousis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen

Author(s) -

Ciaran Skerry,

Michael L. Pinn,

Natalie Bruiners,

Richard Pine,

Maria Laura Gennaro,

Petros C. Karakousis

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku166

Subject(s) - simvastatin , isoniazid , medicine , pharmacology , rifampicin , regimen , tuberculosis , pyrazinamide , in vivo , dosing , rifapentine , mycobacterium tuberculosis , biology , latent tuberculosis , microbiology and biotechnology , pathology

The need to develop new, improved treatments for tuberculosis (TB) remains urgent, and the repurposing of existing drugs represents a possible shortcut to market. Recently, there has been significant interest in host-directed adjuvant therapy to enhance bacillary killing. HMG-CoA reductase inhibitors (statins), which are among the most commonly prescribed drugs, have immunomodulatory properties and improve the clinical outcomes of bacterial infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research